Coronary in Biological Technology

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

... Boston Scientific Corporation ("BSC") of TAXUS(R) coronary stent systems incorporating the drug paclitaxel. ... making them the world's most frequently used coronary stents. Royalty revenue derived from sales of ... entry of new competitors into the drug-eluting coronary stent market during the second half of 2008. As ...

Regado Biosciences Expands Medical Advisory Board

... Medicine, University of Auckland and Director of coronary Care and Green Lane Cardiovascular Research Unit, ... a phase 2a study of REG1 in percutaneous coronary intervention (PCI) and will initiate a rigorous phase 2b program in 3Q09 in patients with Acute coronary Syndrome undergoing PCI (the RADAR trial). ...

Cappella Inc. Secures $17.3 Million Series C Investment

... applications of Cappella's technology in Complex coronary Artery Disease (CAD). Commenting on this ... product offering for the treatment of coronary heart disease. Cappella's impressive management ... novel solutions for the treatment of Complex coronary Artery Disease (CAD) and specifically bifurcation ...

Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system

... TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting coronary Stent System, a highly deliverable, ... (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as ... stenting option in the treatment of small-vessel coronary artery disease," said Mark Turco, M.D., F.A.C.C., ...

FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System

... TAXUS(R) Liberte (R) Atom(TM) Paclitaxel-Eluting coronary Stent System, a highly deliverable, ... (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as ... stenting option in the treatment of small-vessel coronary artery disease," said Mark Turco, M.D., F.A.C.C., ...

Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial

... of the study and showed that patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) and taking prasugrel, as ... 1: Spontaneous heart attack caused by a primary coronary event, such as a plaque rupture in ...

InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR '09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le

... leader, Martin Leon MD. About MGuard(TM) coronary MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The ... structural integrity of the stent. The MGuard(TM) coronary stent provides permanent embolic protection, ...

SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System

... from a substudy of patients with left main coronary disease who were treated with the TAXUS(R) Express(2)(R) Paclitaxel-Eluting coronary Stent System. SYNTAX-LE MANS is a substudy of the ... controlled clinical trial to compare percutaneous coronary intervention (PCI) using the TAXUS Stent ...

Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent

... chromium TAXUS(R) Element(TM) Paclitaxel-Eluting coronary Stent System in select markets worldwide. The ... chromium alloy engineered specifically for coronary stent applications and represents the Company's ... performance in treating patients with complex coronary artery disease. Boston Scientific has reported ...

First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter

... today the first use in patients of a novel coronary catheter that uses both light and sound to image coronary plaques. Working on a team led by Dr. Patrick ... procedures on May 11, 2009 in patients undergoing coronary angiography at the Thoraxcenter. The ...

Boston Scientific Welcomes Launch of Syntax Score Website

... tool used to measure the complexity of coronary artery disease. The Company made the ... controlled clinical trial to compare percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting coronary Stent System ...

Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009

... ("BSC") sales of paclitaxel-eluting coronary stent systems as compared to the first ... its TAXUS Liberte(R) Atom(TM) Paclitaxel-Eluting coronary Stent System and its TAXUS Liberte Long(TM) Paclitaxel-Eluting coronary Stent System to the U.S. Food and Drug ...

VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009

... a sub-study of patients from the Company's acute coronary syndrome (ACS) trial who received serial 64 slice ... P555 Title: Evaluation of coronary Artery Atherosclerotic Plaque ... in Patients with Recent Acute coronary Syndrome Treated for 6 ...

New Discoveries on a Fingertip Test for Screening Silent Heart Disease Promising Results of Recent Clinical Studies to be Presented during the 2009 American College of Cardiology Conference, March 29th - April 1st in Orlando

... changes at the fingertips can help detect hidden coronary artery disease. ... changes at the fingertips can help detect hidden coronary artery disease. Presentation Number: ... Monitoring Strongly Correlates With the Extent of coronary Artery Disease Diagnosed by 64 Slice ...

Boston Scientific Launches New Coronary Imaging Catheter

... ) today announced the launch of its iCross(TM) coronary Imaging Catheter, a product designed to improve ... to see detailed images inside the heart and coronary arteries. The Company said the iCross Catheter ... United States. "Boston Scientific's iCross coronary Imaging Catheter is a powerful tool for ...

Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008

... Boston Scientific Corporation ("BSC") of TAXUS(R) coronary stent systems. This decline in royalty revenue ... property and royalty revenue related to TAXUS(R) coronary stent systems. In connection with this ... but not limited to: changes in drug-eluting coronary stent markets, including the impact of new ...

European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI

... -- Heart patients with acute coronary syndrome (ACS) undergoing an artery-opening ... in patients with ACS undergoing percutaneous coronary intervention (PCI). The approval follows a ... States for the treatment of patients with acute coronary syndromes (ACS) managed with ...

CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer

... catheter and the advanced Valecor Platinum(TM) coronary Stent System. "We needed to put in place ... for production of the Valecor Platinum(TM) coronary Stent (a platinum surface-modified stent), as ... decision making and the Valecor Platinum(TM) coronary Stent, a platinum surface-modified bare-metal ...

VAP Cholesterol Test Helps In Search For New Heart Disease Drugs

... heart disease as evidenced by decreased levels of coronary artery calcification. The association between these improved lipid profiles and decreased coronary artery calcification - an underlying indicator of coronary heart disease - was confirmed using the expanded ...

Traditional Risk Factors Often Miss Heart Disease Warning Signs

... Individuals with a Family History of Premature coronary Heart Disease and Low Framingham Risk Score. It ... age of 47) with a family history of premature coronary heart disease (CHD) and who had a low Framingham ... In addition, 38 percent of the participants had coronary atherosclerosis as reflected in EBCT ...

vProtect(TM) Luminal Shield Stabilizes Life-Threatening Plaque

... Shield in the left anterior descending (LAD) coronary artery of the patient at Erasmus Medical Center ... plaques--"silent" atherosclerotic deposits in the coronary arteries that do not produce symptoms until they ... cath lab for treatment of clinically significant coronary lesions, which are treated according to current ...

Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons

... State-of-the-art CE-Marked Cobalt-Chromium coronary Stent Forms Alliance to Jointly Develop Drug ... rights to Maxcor's Genius MAGIC Cobalt Chromium coronary Stent System for the purpose of developing and ... to deliver a precise therapeutic solution for coronary artery disease without the long-term safety ...

Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial

... in its 500 patient FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation ... product targeting a life-threatening coronary event for which there are limited ... known marker of inflammation. About Acute coronary Syndrome ...

CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East

... in which it is commercializing the CATANIA(TM) coronary Stent System with NanoThin Polyzene(R)-F -- a ... death, myocardial infarction, stroke, or coronary artery bypass graft. Target ... Color-Advanced Microspheres and the CATANIA(TM) coronary Stent System with NanoThin Polyzene(R)-F. ...

Terumo Interventional Systems Launches a Complete Line of Coronary Diagnostic Catheters

... the launch of Optitorque(TM), its new line of coronary diagnostic catheters, featuring the exclusive ... transradial approach. They can be used for left coronary artery, right coronary artery and LV. So, the need for the exchange of ...

FDA Approves Boston Scientific's Apex(TM) PTCA Dilatation Catheter

... coronary atherosclerosis undergoing percutaneous coronary intervention (PCI). Boston Scientific furthers ... patients. PTCA dilatation catheters are used in coronary angioplasty and stenting procedures to open ... left untreated can cause heart attack and stroke. coronary artery disease represents the leading cause of ...

MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008

... -- InspireMD, developers of the novel MGuard(TM) coronary stent system, announced today that MGuard(TM) was ... the demonstrations of the novel MGuard(TM) coronary stent system. Interventional cardiologists eager ... a large thrombus obstructing the right coronary artery. MGuard(TM) was successfully delivered in ...

Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium

... onset heart disease or heart attack. About coronary Artery Disease coronary artery disease (CAD) is an inflammatory disease in which plaque builds up inside the coronary arteries. These arteries supply your heart muscle ...

Abbott's XIENCE V(TM) Drug Eluting Stent Wins Prestigious Chicago Innovation Award

... Award for its XIENCE V(TM) Everolimus Eluting coronary Stent System. Based on the product's ... a significant advance in the treatment of coronary artery disease. Abbott's XIENCE V stent was ... for the nearly 13 million Americans with coronary artery disease, the leading cause of death for ...

Boston Scientific Announces Results for Third Quarter Ended September 30, 2008

... Express2(TM) Atom(TM) Paclitaxel-Eluting coronary Stent System, the first DES for small vessels -- Launched the PROMUS(TM) Everolimus-Eluting coronary Stent System in the U.S. -- Generated $638 ... Worldwide sales of the Company's drug-eluting coronary stent systems for the third quarter of 2008 were ...

Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent

... Liberte(R) Paclitaxel-Eluting coronary Stent System. The Company plans to launch the ... Atom(TM) Paclitaxel-Eluting coronary Stent System, which was approved by the FDA last ... against the Xience(TM) V Everolimus-Eluting coronary Stent System in the SPIRIT II and III trials. ...

Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During 'Live' Case at the Paris Cardiovascular Interventions Course (Francophone) 2008

... (Francophone) Congress. The CATANIA(TM) coronary Stent System carries a CE Mark and is ... Stent is an ideal choice for treating coronary artery disease, including chronic total ... Microspheres and the CATANIA(TM) coronary Stent System with NanoThin Polyzene(R)-F. Other ...

Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels

... TAXUS(R) Express2(TM) Atom(TM) Paclitaxel-Eluting coronary Stent System. The TAXUS Express Atom Stent is a ... (DES) specifically designed for treating small coronary vessels. It is the only DES approved by the FDA ... of its TAXUS(R) Express2(TM) Paclitaxel-Eluting coronary Stent System for the treatment of in-stent ...

InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results

... the first 3 patients in its study of MGuard(TM) coronary stent in acute myocardial infarction. The GUARD ... were implanted successfully with the MGuard(TM) coronary Stent, in the Jagiellonian University Clinic, in ... About MGuard(TM) Coronary The MGuard(TM) coronary stent presents a novel combination of a coronary ...

Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery

... its landmark SYNTAX trial comparing percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(TM) Paclitaxel-Eluting coronary Stent System to contemporary coronary artery bypass graft (CABG) surgery. The overall ...

With the BEAUTIFUL Results, Procoralan* (ivabradine) is the First Antianginal Treatment Shown to Reduce Myocardial Infarction (Heart Attack) and Revascularisation in Stable Coronary Patients

... study: a step further in title coronary Artery Disease ESC Hotline Title: The ... events among patients with stable coronary artery disease and left ... dysfunction) trial have shown that coronary artery disease (CAD) patients with left ...

ICON Medical Imaging Launches New Service to Boost Reliability of Cardiology Studies

... Commercial Imaging Lab to Offer Quantitative coronary Angiographic Analysis With ... core laboratory to offer Quantitative coronary Angiographic (QCA) analysis with an integrated ... the field of imaging within clinical research." coronary angiography is the gold standard for the ...

Ovalum Ltd. Announces Success in Coronary Cases Using CiTop™ ExPander™ Guidewire

... study using the CiTop™ technology in the coronary arteries. Ovalum Ltd., a privately held Israeli ... in traversing chronic total occlusions in the coronary arteries. Rehovot , ... study using the CiTop™ technology in the coronary arteries. Ovalum Ltd., a privately held ...

Abbott Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent

... XIENCE V USA Study to Evaluate Treatment of coronary Artery Disease Patients in ... approved the XIENCE V(TM) Everolimus Eluting coronary Stent System. The XIENCE V USA study ... will become a key advancement in the treatment of coronary artery disease." The XIENCE V USA study is ...

Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System

... Stent System for the treatment of coronary artery disease. The PROMUS Stent is a ... and the TAXUS(R) Liberte(R) Paclitaxel-Eluting coronary Stent System (in international markets), making ... symptomatic heart disease due to de novo native coronary artery lesions (up to 28 mm long) with reference ...